Krystal Biotech’s gene therapy an Orphan Drug in U.S. for cystic fibrosis

The FDA has designated Orphan drug tag to Krystal Biotech (NASDAQ:KRYS), to KB407 for cystic fibrosis. KB407 is an inhaled, repeat-dose gene therapy product

Currently the drug candidate is in preclinical studies and the company plans to file an IND in 2021.

https://seekingalpha.com/news/3606419-krystal-biotech-s-gene-therapy-orphan-drug-in-u-s-for-cystic-fibrosis